NCT01546987 2026-03-06
Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer
Radiation Therapy Oncology Group
Phase 3 Completed
Clinical Trials
10 trialsNCT01809691 2025-12-31
S1216
SWOG Cancer Research Network
Phase 3 Completed
NCT01084655 2019-07-30
Study of TAK-700 in Combination With Docetaxel and Prednisone in Men With Metastatic Castration-Resistant Prostate Cancer
Takeda
Phase 1/2 Completed
NCT01707966 2019-05-15
Orteronel Maintenance Therapy in Patients With Metastatic Castration Resistant Prostate Cancer and Non-progressive Disease After First-line Docetaxel Therapy
Swiss Cancer Institute
Phase 3 Completed
NCT01193257 2018-12-19
Study Comparing Orteronel Plus Prednisone in Participants With Metastatic Castration-Resistant Prostate Cancer.
Takeda
Phase 3 Completed
NCT01666314 2018-03-20
Study in Japan and Ex-Japan to Characterize the Pharmacokinetic and Pharmacodynamic Response to Orteronel (TAK-700) in Chemotherapy-Naive Participants With Castration-Resistant Prostate Cancer
Takeda
Phase 1/2 Completed
NCT01193244 2017-05-17
Study Comparing Orteronel Plus Prednisone in Participants With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Takeda
Phase 3 Completed
NCT01549951 2016-06-01
Study to Investigate the Effects of Orteronel on the QT/QTc Interval in Patients With Metastatic Castration-Resistant Prostate Cancer
Millennium Pharmaceuticals, Inc.
Phase 2 Completed
NCT00569153 2016-04-04
TAK-700
Millennium Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT01046916 2016-04-04
Safety and Efficacy Study of TAK-700 in Patients With Nonmetastatic Castration-resistant Prostate Cancer and a Rising Prostate-specific Antigen
Millennium Pharmaceuticals, Inc.
Phase 2 Completed